欧美精品一区二区三区中文|久久高清国产视频|欧美视频一区二区三区|欧美一区二区三区粉红视频!

    <dl id="qfb0a"></dl>
    <delect id="qfb0a"><b id="qfb0a"><big id="qfb0a"></big></b></delect>

  1. <dl id="qfb0a"></dl>
      <dl id="qfb0a"></dl>
      1. <delect id="qfb0a"><b id="qfb0a"><big id="qfb0a"></big></b></delect>
        當前位置: 首頁 » 資訊 » 行業(yè)動態(tài) » 正文

        Quizartinib研究進展

        發(fā)布日期:2017-11-01   瀏覽次數(shù):0
        核心提示:a href=https://www.medchemexpress.com/Quizartinib.htmlQuizartinib/a產(chǎn)品描述:Quizartinib is a uniquely potent and select
        Quizartinib產(chǎn)品描述:Quizartinib is a uniquely potent and selective Flt3 inhibitor with Kd (FLT3 binding affinity) of 1.6±0.7 nM in Biochemical assay.IC50 & Target: Kd: 1.6±0.7 nM (Flt3)[1]In Vitro: Quizartinib (AC220) is a novel compound expressly optimized as a FLT3 inhibitor for the treatment of acute myeloid leukemia (AML). Quizartinib inhibits FLT3-WT and FLT3-ITD autophosphorylation with IC50 of 4.2±0.3 nM and 1.1±0.1 nM, respectively. Quizartinib inhibits MV4-11 and A375 cells with IC50 of 0.56±0.3 nM and >10 000 nM, respectively. Quizartinib inhibits FLT3 with low nanomolar potency in cellular assays and is highly selective when screened against the majority of the human protein kinome[1]. In Vivo: Quizartinib (AC220) inhibits FLT3 activity in vivo, significantly extends survival in a mouse model of FLT3-ITD AML at doses as low as 1 mg/kg when dosed orally once a day, eradicates tumors in a F


        公司介紹:MedChemExpress(MCE)專注于各種抑制劑、激動劑、API及化合物庫,總部位于美國新澤西,分別在瑞典和上海設有歐洲區(qū)子公司和亞洲區(qū)總代理,營銷網(wǎng)點遍及全球20多個國家地區(qū)。MCE經(jīng)過多年努力已成為全球生物活性小分子領域的一流供應商, 產(chǎn)品涵蓋癌癥、神經(jīng)科學、抗感染、表觀遺傳學等20個熱門研究領域,PI3K、MAPK等近千個細分靶點,超過4000個活性小分子化合物現(xiàn)貨,以及GPCR、API、離子通道等超過20種不同類型的化合物庫,同時提供從毫克到千克的專業(yè)定制合成服務。
        MCE 對每批產(chǎn)品都進行嚴格的LCMS和NMR檢驗,其產(chǎn)品已被全球近萬名客戶廣泛使用并發(fā)表大量文章、專利;
        MCE 定期增加各領域熱門抑制劑、激動劑,不斷擴增已有化合物庫,以滿足最新的科研需求;
        數(shù)千種產(chǎn)品在上海有充足備貨,24-48小時內送達客戶;
        大量產(chǎn)品提供免費試用裝;已為全球多個知名企業(yè)、院校構建各種定制型化合物庫。

        產(chǎn)品鏈接:www.medchemexpress.cn/quizartinib.html

         
         
         
        ?